apoioI

data

sexta, 20 maio 2016 16:14
Atualidade

O futuro da medicina personalizada e da investigação oncológica

O programa da ASCO 2016 contempla os mais recentes avanços na medicina personalizada e imuno-oncologia, bem como as novas abordagens que tornam as terapêuticas convencionais do cancro mais benéficas para os doentes.

O programa do evento garante uma oferta diversificada no âmbito da oncologia, incluindo temas como: medicina de precisão, qualidade de vida dos doentes oncológicos, imunoterapia, novas abordagens terapêuticas no contexto do tratamento convencional. Destaca-se ainda, uma sessão plenária que engloba apresentações didáticas de elevada qualidade científica e com impacto na prática clínica.

Novas abordagens com terapias convencionais

› Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin (abstract LBA503).

› Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial (abstract LBA2000).

› Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results (abstract LBA509).

› OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC) (abstract LBA5503).

› SPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma (abstract LBA4006).

Medicina de Precisão

› Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA (abstract LBA11501).

› Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study (abstract LBA11511).

› The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research (abstract LBA1519).

Imuno-Oncologia

› Results from a phase II study investigating the PD-L1 inhibitor atezolizumab as first-line therapy for patients with advanced bladder cancer who cannot safely undergo standard therapy (abstract LBA4500).

› FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma (abstract LBA4001).

› Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC) (abstract LBA8505).

› Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma (abstract LBA3010).

Melhoria da qualidade e do acesso ao tratamento

› Overall survival in patients with lung cancer using a web-application-guided follow-up compared to standard modalities: Results of phase III randomized trial (abstract LBA9006).

› Aggressive care at the end-of-life for younger patients with cancer: Impact of ASCO’s Choosing Wisely campaign (abstract 10033).

› Disparities in cancer risk management amongBRCAcarriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors (abstract LBA1504).

› Global differences in cancer drug prices: A comparative analysis (abstract LBA 6500).

Store News Farma

Newsletter

Área Reservada

Os portugueses na ASCO 2016

Dr.ª Ana Castro

Dr. José Duro da Costa

Dr.ª Fátima Cardoso

Dr.ª Lourdes Barradas

Dr.ª Maria Teresa

Prof. Doutor Venceslau Hespanhol

Dr. Sérgio Barroso

Dr. Hélder Mansinho

Prof. Doutor António Araújo

Dr.ª Gabriela Sousa

Dr.ª Mónica Nave

Dr.ª Teresa Timoteo

Prof. Doutor José Passos Coelho